Akebia Therapeutics
↗Cambridge, USA
Akebia Therapeutics is a fully integrated biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease. The company is best known for its work in the renal space, specifically addressing anemia associated with chronic kidney disease (CKD) and hyperphosphatemia.
Following the FDA approval of its lead product, Vafseo (vadadustat), in early 2024, Akebia has transitioned into a commercial-stage entity. The company is currently pivoting its R&D strategy toward rare kidney diseases, leveraging its established nephrology sales force to market new assets acquired through strategic partnerships and acquisitions.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Revenue:$236.2M (2025)
Founded:2007
Ownership:public
Status:operating
FUNDING
Stage:Public
Total Raised:$340.9M
Investors:Genechem, Abingworth, Novo Holdings, SROne
STOCK
Exchange:NASDAQ
Ticker:AKBA
Market Cap:$337.5M
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial (Vafseo)
Modalities:Small molecule, Monoclonal antibody fusion protein
Active Trials:66
Trial Phases:Phase 1: 1 | Phase 2: 2 | Phase 3: 2 | Phase 4: 1
FDA Approvals:2
EMA Approvals:1
CORPORATE STRUCTURE
Key Partnerships:CSL Vifor (Commercialization partner for Vafseo), Mitsubishi Tanabe Pharma (Partner in Japan/Asia), Medice (Partner in Europe)
COMPETITION
Position:Challenger
Competitors:GSK (Duvroq), AstraZeneca (Evrenzo), FibroGen, Travere Therapeutics, Calliditas Therapeutics
LEADERSHIP
Key Executives:
John P. Butler - CEO
Erik Ostrowski - CFO & CBO
Scientific Founders:Marc Otte, Doug Harker
Board Members:Adrian Adams (Chair), Cynthia Smith, LeAnne M. Zumwalt, Michael Rogers
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Akebia Therapeutics. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.